Search Results - "LANTUEJOUL, Sylvie"

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial by Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Lantuejoul, Sylvie, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Guisier, Florian, Urban, Thierry, Ligeza-Poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gérard, DEBIEUVRE, Didier, HIRET, Sandrine, CADRANEL, Jacques, FRABOULET-MOREAU, Séverine, CARMIER, Delphine

“…There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease…”
Get full text

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 by Nicholson, Andrew G, Tsao, Ming S, Beasley, Mary Beth, Borczuk, Alain C, Brambilla, Elisabeth, Cooper, Wendy A, Dacic, Sanja, Jain, Deepali, Kerr, Keith M, Lantuejoul, Sylvie, Noguchi, Masayuki, Papotti, Mauro, Rekhtman, Natasha, Scagliotti, Giorgio, van Schil, Paul, Sholl, Lynette, Yatabe, Yasushi, Yoshida, Akihiko, Travis, William D

“…The 2021 WHO Classification of Thoracic Tumours was published earlier this year, with classification of lung tumors being one of the chapters. The principles…”
Get more information

Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma by Gout, Stephanie, Brambilla, Elisabeth, Boudria, Asma, Drissi, Romain, Lantuejoul, Sylvie, Gazzeri, Sylvie, Eymin, Beatrice

“…Splicing abnormalities frequently occur in cancer. A key role as splice site choice regulator is played by the members of the SR (Ser/Arg-rich) family of…”
Get full text

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) by Barlesi, Fabrice, Dr Prof, Mazieres, Julien, Prof, Merlio, Jean-Philippe, Prof, Debieuvre, Didier, MD, Mosser, Jean, Prof, Lena, Hervé, MD, Ouafik, L'Houcine, Prof, Besse, Benjamin, MD, Rouquette, Isabelle, MD, Westeel, Virginie, Prof, Escande, Fabienne, MD, Monnet, Isabelle, MD, Lemoine, Antoinette, Prof, Veillon, Rémi, MD, Blons, Hélène, PharmD, Audigier-Valette, Clarisse, MD, Bringuier, Pierre-Paul, Prof, Lamy, Régine, MD, Beau-Faller, Michèle, MD, Pujol, Jean-Louis, Prof, Sabourin, Jean-Christophe, Prof, Penault-Llorca, Frédérique, Prof, Denis, Marc G, Prof, Lantuejoul, Sylvie, Prof, Morin, Franck, MSc, Tran, Quân, MSc, Missy, Pascale, PhD, Langlais, Alexandra, MSc, Milleron, Bernard, MD, Cadranel, Jacques, Prof, Soria, Jean-Charles, Prof, Zalcman, Gérard, Prof

“…Summary Background The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during…”
Get full text

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee by Lantuejoul, Sylvie, Sound-Tsao, Ming, Cooper, Wendy A, Girard, Nicolas, Hirsch, Fred R, Roden, Anja C, Lopez-Rios, Fernando, Jain, Deepali, Chou, Teh-Ying, Motoi, Noriko, Kerr, Keith M, Yatabe, Yasushi, Brambilla, Elisabeth, Longshore, John, Papotti, Mauro, Sholl, Lynette M, Thunnissen, Erik, Rekhtman, Natasha, Borczuk, Alain, Bubendorf, Lukas, Minami, Yuko, Beasley, Mary Beth, Botling, Johan, Chen, Gang, Chung, Jin-Haeng, Dacic, Sanja, Hwang, David, Lin, Dongmei, Moreira, Andre, Nicholson, Andrew G, Noguchi, Masayuki, Pelosi, Giuseppe, Poleri, Claudia, Travis, William, Yoshida, Akihiko, Daigneault, Jillian B, Wistuba, Ignacio I, Mino-Kenudson, Mari

“…The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or…”
Get more information

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee by Sholl, Lynette M, Hirsch, Fred R, Hwang, David, Botling, Johan, Lopez-Rios, Fernando, Bubendorf, Lukas, Mino-Kenudson, Mari, Roden, Anja C, Beasley, Mary Beth, Borczuk, Alain, Brambilla, Elisabeth, Chen, Gang, Chou, Teh-Ying, Chung, Jin-Haeng, Cooper, Wendy A, Dacic, Sanja, Lantuejoul, Sylvie, Jain, Deepali, Lin, Dongmei, Minami, Yuko, Moreira, Andre, Nicholson, Andrew G, Noguchi, Masayuki, Papotti, Mauro, Pelosi, Giuseppe, Poleri, Claudia, Rekhtman, Natasha, Tsao, Ming-Sound, Thunnissen, Erik, Travis, William, Yatabe, Yasushi, Yoshida, Akihiko, Daigneault, Jillian B, Zehir, Ahmet, Peters, Solange, Wistuba, Ignacio I, Kerr, Keith M, Longshore, John W

“…Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response…”
Get more information

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer by Brambilla, Elisabeth, Le Teuff, Gwénaël, Marguet, Sophie, Lantuejoul, Sylvie, Dunant, Ariane, Graziano, Stephen, Pirker, Robert, Douillard, Jean-Yves, Le Chevalier, Thierry, Filipits, Martin, Rosell, Rafael, Kratzke, Robert, Popper, Helmut, Soria, Jean-Charles, Shepherd, Frances A, Seymour, Lesley, Tsao, Ming Sound

“…Tumor lymphocytic infiltration (TLI) has differing prognostic value among various cancers. The objective of this study was to assess the effect of TLI in lung…”
Get full text

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer by Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., Penault-Llorca, F., Lantuéjoul, S.

“…Various programed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays have been developed and used in clinical trials in association with different drugs…”
Get full text

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection by Tsao, Ming-Sound, Marguet, Sophie, Le Teuff, Gwénaël, Lantuejoul, Sylvie, Shepherd, Frances A, Seymour, Lesley, Kratzke, Robert, Graziano, Stephen L, Popper, Helmut H, Rosell, Rafael, Douillard, Jean-Yves, Le-Chevalier, Thierry, Pignon, Jean-Pierre, Soria, Jean-Charles, Brambilla, Elisabeth M

“…The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European…”
Get full text

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee by Mino-Kenudson, Mari, Schalper, Kurt, Cooper, Wendy, Dacic, Sanja, Hirsch, Fred R, Jain, Deepali, Lopez-Rios, Fernando, Tsao, Ming Sound, Yatabe, Yasushi, Beasley, Mary Beth, Yu, Hui, Sholl, Lynette M, Brambilla, Elizabeth, Chou, Teh-Ying, Connolly, Casey, Wistuba, Ignacio, Kerr, Keith M, Lantuejoul, Sylvie

“…Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or metastatic disease. In…”
Get more information

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens by Lukas Bubendorf, Sylvie Lantuejoul, Adrianus J. de Langen, Erik Thunnissen

“…The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small…”
Get full text

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer by Smeltzer, Matthew P, Wynes, Murry W, Lantuejoul, Sylvie, Soo, Ross, Ramalingam, Suresh S, Varella-Garcia, Marileila, Meadows Taylor, Meghan, Richeimer, Kristin, Wood, Kelsey, Howell, Kristen E, Dalurzo, Mercedes Lilana, Felip, Enriqueta, Hollenbeck, Gina, Kerr, Keith, Kim, Edward S, Mathias, Clarissa, Pacheco, Jose, Postmus, Pieter, Powell, Charles, Tsuboi, Masahiro, Wistuba, Ignacio I, Wakelee, Heather A, Belani, Chandra P, Scagliotti, Giorgio V, Hirsch, Fred R

“…Access to targeted therapies for lung cancer depends on the accurate identification of patients' biomarkers through molecular testing. The International…”
Get more information

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas by Le Loarer, Francois, Watson, Sarah, Pierron, Gaelle, de Montpreville, Vincent Thomas, Ballet, Stelly, Firmin, Nelly, Auguste, Aurelie, Pissaloux, Daniel, Boyault, Sandrine, Paindavoine, Sandrine, Dechelotte, Pierre Joseph, Besse, Benjamin, Vignaud, Jean Michel, Brevet, Marie, Fadel, Elie, Richer, Wilfrid, Treilleux, Isabelle, Masliah-Planchon, Julien, Devouassoux-Shisheboran, Mojgan, Zalcman, Gerard, Allory, Yves, Bourdeaut, Franck, Thivolet-Bejui, Francoise, Ranchere-Vince, Dominique, Girard, Nicolas, Lantuejoul, Sylvie, Galateau-Sallé, Francoise, Coindre, Jean Michel, Leary, Alexandra, Delattre, Olivier, Blay, Jean Yves, Tirode, Franck

“…Francois Le Loarer, Franck Tirode and colleagues identify a new class of undifferentiated thoracic sarcomas characterized by inactivation of SMARCA4 , which…”
Get full text

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group by Thunnissen, Erik, Kerr, Keith M, Herth, Felix J.F, Lantuejoul, Sylvie, Papotti, Mauro, Rintoul, Robert C, Rossi, Giulio, Skov, Birgit G, Weynand, Birgit, Bubendorf, Lukas, Katrien, Grünberg, Johansson, Leif, López-Ríos, Fernando, Ninane, Vincent, Olszewski, Włodzimierz, Popper, Helmut, Jaume, Sauleda, Schnabel, Philipp, Thiberville, Luc, Laenger, Florian

“…Highlights ► The diagnosis of lung cancer involves the identification and complete classification of malignancy. ► New therapeutic options require specific…”
Get full text

Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers by Rousseaux, Sophie, Debernardi, Alexandra, Jacquiau, Baptiste, Vitte, Anne-Laure, Vesin, Aurélien, Nagy-Mignotte, Hélène, Moro-Sibilot, Denis, Brichon, Pierre-Yves, Lantuejoul, Sylvie, Hainaut, Pierre, Laffaire, Julien, de Reyniès, Aurélien, Beer, David G, Timsit, Jean-François, Brambilla, Christian, Brambilla, Elisabeth, Khochbin, Saadi

“…Activation of normally silent tissue-specific genes and the resulting cell "identity crisis" are the unexplored consequences of malignant epigenetic…”
Get more information

Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society by Jain, Deepali, Allen, Timothy Craig, Aisner, Dara L, Beasley, Mary Beth, Cagle, Philip T, Capelozzi, Vera Luiza, Hariri, Lida P, Lantuejoul, Sylvie, Miller, Ross, Mino-Kenudson, Mari, Monaco, Sara E, Moreira, Andre, Raparia, Kirtee, Rekhtman, Natasha, Roden, Anja Christiane, Roy-Chowdhuri, Sinchita, da Cunha Santos, Gilda, Thunnissen, Erik, Troncone, Giancarlo, Vivero, Marina

“…- Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a very useful tool in the field of diagnostic respiratory…”
Get full text

Pulmonary preneoplasia - sequential molecular carcinogenetic events by Lantuéjoul, Sylvie, Salameire, Dimitri, Salon, Caroline, Brambilla, Elisabeth

“…Bronchial and bronchioloalveolar carcinogenesis is a multicentric and multistep process, leading to a sequential accumulation of molecular and genetic…”
Get full text

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study by McLeer-Florin, Anne, Moro-Sibilot, Denis, Melis, Adrien, Salameire, Dimitri, Lefebvre, Christine, Ceccaldi, Françoise, de Fraipont, Florence, Brambilla, Elisabeth, Lantuejoul, Sylvie

“…In 2011, the French National Cancer Institute recommended ALK-fluorescence in situ hybridization (FISH) testing in all EGFR/KRAS-negative adenocarcinomas by…”
Get more information

Analysis of a pituitary tumour with histological features of central neurocytoma points towards the emergence of a new entity recognisable by a specific epigenetic signature by Godfraind, Catherine, Marie, Coutelier, Pissaloux, Daniel, Fabien, Forest, Vandenbos, Fanny, Hasselblatt, Martin, Boutonnat, Jean, Aurélien, Coste, Sylvie, Lantuejoul, Anne, Mc Leer

Get full text

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society by Sholl, Lynette M, Aisner, Dara L, Allen, Timothy Craig, Beasley, Mary Beth, Borczuk, Alain C, Cagle, Philip T, Capelozzi, Vera, Dacic, Sanja, Hariri, Lida, Kerr, Keith M, Lantuejoul, Sylvie, Mino-Kenudson, Mari, Raparia, Kirtee, Rekhtman, Natasha, Roy-Chowdhuri, Sinchita, Thunnissen, Eric, Tsao, Ming Sound, Yatabe, Yasushi

“…The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target…”
Get full text